Sanofi (SNY)
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
- Symbol
- SNY
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- 52 week range
- 40.89 - 52.68
Valuation
- Share price
- $41.66 (close of 2026-09-23)
- P/E (TTM)
- 11.63x
- Price to book
- 1.27x
- Price to free cash flow
- 12.59x
Price performance
| Period | Change |
|---|---|
| 1 day | -1.98% |
| 5 days | -1.75% |
| 1 month | -9.14% |
| 3 months | +0.14% |
| 6 months | -6.95% |
| Year to date | -14.03% |
| 1 year | -11.13% |
| 3 years | -22.88% |
| 5 years | -14.49% |
| 10 years | +8.63% |
| All time | +39.94% |
Profitability and growth
- Return on equity
- 10.90%
- Return on invested capital
- 6.28%
- Return on assets
- 6.16%
- Return on capital employed
- 6.44%
- Gross margin
- 77.17%
- Net margin
- 17.91%
- EBITDA margin
- 14.54%
- Revenue growth
- 6.20%
- Net income growth
- 40.52%
- Free cash flow growth
- 22.53%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 7.94%
- Current ratio
- 1.09x
- Net debt to EBITDA
- 1.02x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Shares outstanding
- 2.44B
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 77.17% | 17.91% | 10.90% | 6.28% |
| 2024-12-31 | 75.66% | 13.53% | 7.14% | 6.85% |
| 2023-12-31 | 76.66% | 14.28% | 7.26% | 7.07% |
| 2022-12-31 | 76.17% | 22.23% | 11.14% | 9.87% |
| 2021-12-31 | 71.29% | 16.48% | 9.01% | 8.40% |
| 2020-12-31 | 69.95% | 34.11% | 19.44% | 17.52% |
| 2019-12-31 | 71.01% | 7.62% | 4.65% | 4.12% |
| 2018-12-31 | 70.34% | 12.49% | 7.29% | 5.66% |
| 2017-12-31 | 70.16% | 24.00% | 14.45% | 6.56% |
| 2016-12-31 | 70.97% | 13.93% | 8.16% | 8.10% |
Investor relations
Next earnings report
- Next confirmed report
- 2026-10-30
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-07-30 | Jun/2026 | - |
| 2026-04-23 | - | - |
| 2026-01-29 | - | - |
| 2025-10-24 | - | - |
| 2025-07-31 | - | - |
| 2025-04-24 | - | - |
| 2025-01-30 | - | - |
| 2024-10-25 | - | - |
Filings and sources
- Company website
- sanofi.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE) · Bristol Myers Squibb Co (BMY)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades